Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin

INTRODUCTION: Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, has demonstrated sustained improvements in glycemic control and body weight reductions with treatment for up to 104 weeks in a broad range of patients with type 2 diabetes mellitus (T2DM). METHODS: This was a post hoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Leiter, Lawrence A., Langslet, Gisle, Vijapurkar, Ujjwala, Davies, Michael J., Canovatchel, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900973/
https://www.ncbi.nlm.nih.gov/pubmed/26984361
http://dx.doi.org/10.1007/s13300-016-0163-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900973/
https://www.ncbi.nlm.nih.gov/pubmed/26984361
http://dx.doi.org/10.1007/s13300-016-0163-1

Ejemplares similares